Cost-Effectiveness of Implantable Cardioverter-Defibrillators

Sudden Cardiac Death: A handbook for clinical practice

Volumn , Issue , 2009, Pages 263-279

  Boriani, Giuseppe ^a   Larsen, Greg ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiac resynchronization therapy; Cardioversion defibrillation capabilities; Cost effectiveness analysis to evaluate the cost of any therapeutic intervention; Pharmacological treatments; Reduced implantation costs

Indexed keywords

EID: 84889438819     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312881.ch18     Document Type: Chapter

References (59)

1. Cohen JW, Krauss NA. Spending and service use among people with the fifteen most costly medical conditions, 1997. Health Affairs 2003; 22: 129-138.
2. Ryden L, Stokoe G, Breithardt G et al. Patient access to medical technology across Europe. Eur Heart J 2004; 25: 611-616.
3. Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358: 993-998.
4. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med 2004; 350: 2196-2198.
5. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation 2002; 106: 516-520.
6. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation 2002; 106: 626-630.
7. Hlatky MA. Evidence-based use of cardiac procedures and devices. N Engl J Med 2004; 350: 2126-2128.
8. Kupersmith J. Cost-effective strategies in cardiology. In: Hurst JW, et al., eds. The Heart, Arteries and Veins, 9th edn. McGraw-Hill, New York, 1998: 2557-2578.
9. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. RiskAnalysis 1995; 15: 369-390.
10. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336.
11. Boriani G, Biffi M, Martignani C et al. Cost-effectiveness of implantable cardioverter-defibrillators. Eur Heart J 2001; 22: 990-996.
12. Gaspoz JM, Coxson PG, Goldman PA et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. NEngl J Med 2002; 346: 1800-1806.
13. Zipes DP, Wellens HJJ. What have we learned about cardiac arrhythmias? Circulation 2000; 102: IV52-IV57.
14. Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). J Am Coll Cardiol 2002; 40: 1703-1719.
15. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 16: 1374-1450.
16. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003; 24: 13-15.
17. Boriani G, Frabetti L, Biffi M et al. Clinical experience with downsized lower energy output implantable cardioverter-defibrillators. Int J Cardiol 1998; 66: 261-266.
18. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med 2003; 349: 1836-1847.
19. Zipes DP. Implantable cardioverter-defibrillator: a Volkswagen or a Rolls Royce - how much will we pay to save a life? Circulation 2001; 103: 1372-1374.
20. Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002; 346: 931-933.
21. Boriani G, Biffi M, Martignani C, et al. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Failure 2003; 5: 419-425.
22. Reynolds MR, Josephson ME. MADIT II (second Multicenter Automated Defibrillator Implantation Trial) debate: risk stratification, costs, and public policy. Circulation 2003; 108: 1779-1783.
23. The Antiarrhythmic Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.
24. Kuck KH, Cappato R, Siebels J et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754.
25. Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.
26. Connolly SJ, Hallstrom AP, Cappato R et al. Meta-analysis of the implantable cardioverter-defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics Versus Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.
27. Moss AJ, Hall J, Cannom DS et al. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940.
28. Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. N Engl J Med 1999; 341: 1882-1890.
29. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
30. Bristow MR, Saxon LA, Boehmer J et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
31. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
32. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880.
33. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
34. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure. A meta-analysis of randomized controlled trials. JAMA 2003; 289: 730-740.
35. McAlister FA, Ezekowitz JA, Wiebe N et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 381-390.
36. Boriani G, Biffi M, Martignani C et al. Cardiac resynchronization by pacing: an electrical treatment of heart failure. Int J Cardiol 2004; 94: 151-161.
37. Auricchio A, Abraham WT. Cardiac resynchronization therapy: current state of the art: cost versus benefit. Circulation 2004; 109: 300-307.
38. Zipes DP. Guidelines: tools for building better patient care. J Am Coll Cardiol 2001; 38: 2088-2090.
39. Ruskin JN, Camm AJ, Zipes DP, et al. Implantable cardioverter defibrillator utilization based on discharge diagnoses from Medicare and managed care patients. J Cardiovasc Electrophysiol 2002; 13: 38-43.
40. Simoons ML. Cardiovascular diseases in Europe: challenges for the medical profession. Eur Heart J 2003; 24: 8-12.
41. Schwartz PJ, Breithardt G, Howard J, et al. The legal implications of medical guidelines. A task force of the European Society of Cardiology. Eur Heart J 1999; 20: 1152-1157.
42. Mushlin AI, Hall J, Zwanziger J, Gajang E, et al. The cost-effectiveness of implantable cardiac defibrillators: results from MADIT. Multicentre Automatic Defibrillator Trial. Circulation 1998; 97: 2129-2135.
43. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter-defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001; 135: 870-883.
44. O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator. Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001; 103: 1416-1421.
45. Sheldon R, O'Brien BJ, Blackhouse G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001; 104: 1622-1626.
46. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratification on costeffectiveness of the implantable cardioverter-defibrillator. Am Heart J 2002; 144: 440-448.
47. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias. Circulation 2002; 105: 2049-2057.
48. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost-effectiveness of implantable cardioverter-defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. Am J Med 2002; 112: 519-527.
49. Chen L, Hay JW. Cost-effectiveness of primary implantable cardioverterdefibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drug Ther 2004; 18: 161-170.
50. Mark DB. Cost-effectiveness of ICD therapy in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Presented at the Late Breaking Trials session of the Annual Meeting of the American Heart Association, New Orleans, November 10, 2004.
51. Lynd LD, O'Brien BJ. Cost-effectiveness of the implantable cardioverterdefibrillator: a review of current evidence. J Cardiovasc Electrophysiol 2003; 14: S99-S103.
52. Hlatky MA, Bigger JT. Cost-effectiveness of the implantable cardioverter defibrillator. Lancet 2001; 357: 1817-1818.
53. Jauhar S, Slotwiner DJ. The economics of ICDs. NEngl J Med 2004; 351: 2542-2544.
54. Salukhe TV, Dimopoulos K, Sutton R, et al. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation 2004; 109: 1848-1853.
55. Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004; 110: 112-116.
56. Boriani G, Biffi M, Martignani C. Letter regarding article by Bokhari, et al. "Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS)." Circulation 2005; 111: e26.
57. Boriani G, Maron B, Shen WK, et al. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation 2004; 110: e438-e442.
58. Moss AJ. Findings in MADIT II substudies. Eur Heart J Suppl 2003; 5: I34-I38.
59. Nicol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343-351.